Effect of Vitamin D on Morbidity and Mortality of the COVID-19

Phase 4 Unknown 80 enrolled Fundación para la Investigación Biosanitaria del Principado de Asturias Hospital Universitario Central de Asturias · collab Instituto de Investigación Sanitaria del Principado de Asturias · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19). Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.

Timeline

Start: 2020-04-04
Primary completion: 2020-09-14
Completion: 2020-12-30

Publications

Cannata-Andia JB, Diaz-Sottolano A, Fernandez P, Palomo-Antequera C, Herrero-Puente P, Mouzo R, Carrillo-Lopez N, Panizo S, Ibanez GH, Cusumano CA, Ballarino C, Sanchez-Polo V, Pefaur-Penna J, Maderuelo-Riesco I, Calvino-Varela J, Gomez MD, Gomez-Alonso C, Cunningham J, Naves-Diaz M, Douthat W, Fernandez-Martin JL; COVID-VIT-D trial collaborators. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial. BMC Med. 2022 Feb 18;20(1):83. doi: 10.1186/s12916-022-02290-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Cholecalciferol	Other / unclassified	100000 iu	Oral

Effect of Vitamin D on Morbidity and Mortality of the COVID-19

Summary

Timeline

Publications

Drugs

Indications